Thomas Meyer, CEO of Altamira Therapeutics CYTO, was recently a guest on Benzinga’s All-Access.
Altamira develops RNA-based therapeutics for extrahepatic targets. The company also has legacy programs in allergy and viral infections and inner ear disorders, which it intends to partner on as it plans to focus exclusively on the exciting opportunities in RNA.
RNA therapies are extremely effective for a host of indications. However, actually delivering that therapy is still a hurdle the medical community is attempting to solve. Altamira has developed its “OligoPhore” and “SemaPhore” technologies to change this.
Watch the full interview here:
This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.